Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adagrasib ± pembrolizumab versus pembrolizumab in KRAS G12C-mutated advanced NSCLC
2023-508922-83-00Phase 3Authorised
- Sponsor
- Mirati Therapeutics
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
- Countries
- 27
01
Overview
Phase 3, randomised trial of adagrasib and pembrolizumab in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Mirati Therapeutics. Planned start Oct 2024; status: authorised.
02
Drugs
adagrasibpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-508922-83-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508922-83-00.